Alfacalcidol IV vs PO

• There is no good evidence to support that IV is superior over PO in terms of therapeutic superiority and improvements in clinical outcomes
• IV is more costly than PO form (about 6-8 times more)
• In one study, it supports the use of PO alfalcidol over IV in chronic haemodialysis patients as PO administration gives similar control of SHPT with lower doses, and is more cost-effective.

References:

1. Alfacalcidol intravenous injection. http://www.health.gov.on.ca/en/pro/programs/drugs/ced/pdf/one_alpha.pdf

2. Comparison of oral and intravenous Alfacalcidol in chronic haemodialysis patients. http://www.biomedcentral.com/1471-2369/15/27